Literature DB >> 2783363

The rapid induction by interleukin-2 of pulmonary microvascular permeability.

J M Klausner1, N Morel, I S Paterson, L Kobzik, C R Valeri, T J Eberlein, D Shepro, H B Hechtman.   

Abstract

The clinical use of interleukin-2 (IL-2) is limited by severe cardiopulmonary dysfunction. This study examines the mechanism of respiratory failure related to IL-2, using sheep with chronic lung lymph fistulae. Awake animals were infused with an intravenous (I.V.) bolus of IL-2 10(5) U/kg (n = 5) or its excipient (EXC) control (n = 3), every 8 hours for 4 to 5 days. Cardiopulmonary function was monitored daily for at least one 8-hour period. Within 2 hours after each IL-2 administration, mean pulmonary arterial pressure (MPAP) rose. On Day 1, the mean rise was from 13 to 26 mmHg (p less than 0.05), and on Day 5, to 29 mmHg (p less than 0.05). MPAP returned to baseline levels after 2-3 hours. Pulmonary arterial wedge pressure was unchanged from 4 mmHg. There were transient falls in arterial oxygen tension, from 88 to 77 mmHg on Day 1 and to 73 mmHg (p less than 0.05) on Day 5. Lung lymph flow (QL) rose from 2.4 to 6.8 ml/30 minutes (p less than 0.05) on Day 1, and from 4.7 to 10.2 ml/30 minutes (p less than 0.05) on Day 5, whereas the lymph/plasma protein ratio increased on Day 1 from 0.69 to 0.83 (p less than 0.05) and from 0.63 to 0.71 (p less than 0.05) on Day 5. This documents an increase in pulmonary microvascular permeability. Thromboxane (Tx)B2 levels increased transiently after each IL-2 injection in plasma from 195 to 340 pg/ml (p less than 0.05) and in lung lymph from 222 to 772 pg/ml (p less than 0.05) on Day 1, and to similar levels on Day 5. There was a progressive rise in cardiac output from 5.7 to 8.6 1/minute (p less than 0.05) during the 5 days of infusion. Systemic blood pressure did not change. Temperature rose from 39.1 to 41.2 C (p less than 0.05), and shaking chills were common. There was a progressive fall in leukocyte count, from 8.4 to 3.2 X 10(3)/mm3 (p less than 0.05) by Day 5, reflecting a 77% fall in lymphocytes. Lung lymph lymphocyte counts rose, and lymphocyte clearance increased.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2783363      PMCID: PMC1493893          DOI: 10.1097/00000658-198901000-00017

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  34 in total

1.  Preparation of chronic lung lymph fistulas in sheep.

Authors:  N C Staub; R D Bland; K L Brigham; R Demling; A J Erdmann; W C Woolverton
Journal:  J Surg Res       Date:  1975-11       Impact factor: 2.192

2.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

Review 3.  Pulmonary edema.

Authors:  N C Staub
Journal:  Physiol Rev       Date:  1974-07       Impact factor: 37.312

4.  The pulmonary and systemic response to recurrent endotoxemia in the adult sheep.

Authors:  R H Demling; C C Lalonde; L J Jin; J Albes; N Fiori
Journal:  Surgery       Date:  1986-11       Impact factor: 3.982

5.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

6.  Eicosanoid modulation of stress fibers in cultured bovine aortic endothelial cells.

Authors:  S L Welles; D Shepro; H B Hechtman
Journal:  Inflammation       Date:  1985-12       Impact factor: 4.092

7.  Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2.

Authors:  M Rosenstein; S E Ettinghausen; S A Rosenberg
Journal:  J Immunol       Date:  1986-09-01       Impact factor: 5.422

8.  Clinical effects and toxicity of interleukin-2 in patients with cancer.

Authors:  M T Lotze; Y L Matory; A A Rayner; S E Ettinghausen; J T Vetto; C A Seipp; S A Rosenberg
Journal:  Cancer       Date:  1986-12-15       Impact factor: 6.860

9.  Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis.

Authors:  P R Craddock; J Fehr; K L Brigham; R S Kronenberg; H S Jacob
Journal:  N Engl J Med       Date:  1977-04-07       Impact factor: 91.245

10.  Serotonin, norepinephrine, and histamine mediation of endothelial cell barrier function in vitro.

Authors:  D Bottaro; D Shepro; S Peterson; H B Hechtman
Journal:  J Cell Physiol       Date:  1986-08       Impact factor: 6.384

View more
  5 in total

1.  Haemodynamic effects induced by intravenous administration of high doses of r-Met Hu IL-2 [ala-125] in patients with advanced cancer.

Authors:  D Diana; J P Sculier
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

2.  Involvement of thromboxane and neutrophils in multiple-system organ edema with interleukin-2.

Authors:  R Welbourn; G Goldman; L Kobzik; C R Valeri; D Shepro; H B Hechtman
Journal:  Ann Surg       Date:  1990-12       Impact factor: 12.969

3.  Interleukin-2 induces early multisystem organ edema mediated by neutrophils.

Authors:  R Welbourn; G Goldman; L Kobzik; I Paterson; D Shepro; H B Hechtman
Journal:  Ann Surg       Date:  1991-08       Impact factor: 12.969

4.  Platelet activating factor mediates interleukin-2-induced lung injury in the rat.

Authors:  R Rabinovici; M D Sofronski; J F Renz; L M Hillegas; K M Esser; J Vernick; G Feuerstein
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

5.  Effect of interleukin 2 on urinary excretion of degradation products of prostacyclin and thromboxane A2 in patients with ovarian cancer.

Authors:  A Aitokallio-Tallberg; P Lehtovirta; J Vartiainen; O Ylikorkala
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.